ARYLSULFONANILIDE PHOSPHATES

Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.

Description: ARYLSULFONANILIDE PHOSPHA TES FIELD OF THE INVENTION The present invention relates to arylsulfonani de phosphates, deπvatives and analogs and their use as pharmacologically active agents capable of loweπng plasma cholesterol levels and inhibiting abnormal cell proliferation. BACKGROUND Atherosclerosis is a leading cause of death in the United States The disease results from excess cholesterol accumulation in the arterial walls, which forms plaques that inhibit blood flow and promote clot formation, ultimately causing heart attacks, stroke and claudication A pπncipal source of these cholesterol deposits is the low-density poprotem (LDL) particles that are present m the blood There is a direct correlation between LDL concentration and plaque formation in the arteπes. LDL concentration is itself largely regulated by the supply of active LDL cell surface receptors, which bind LDL particles and translocate them from the blood into the cell's inteπor Accordingly, the upregulation of LDL receptor expression provides an important therapeutic target. Lipoprotein disorders have been previously called the hyperhpoproteinemias and defined as the elevation of a lipoprotein level above normal. The hyperhpoproteinemias result in elevations of cholesterol, tπglyceπdes or both, and are clinically important because of their contπbution to atherosclerotic diseases and pancreatitis. Lφoproteins are spheπcal macromolecular complexes of pid and protein. The hpid constituents of hpoproteins are esteπfied and unesteπfied (free) cholesterol, tπglyceπdes, and phosphohpids. Lipoproteins transport cholesterol and tπglyceπdes from sites of absorption and synthesis to sites of utilization Cholesteryl esters and tπglyceπdes are nonpolar and constitute the hydrophobic core of lipoproteins in varying proportions The lipoprotein surface coat contains the polar constituents - free cholesterol, phosphohpids, and apo poproteins - that permit these particles to be miscible in plasma. Cholesterol is used for the synthesis of bile acids in the liver, the manufacture and repair of cell membranes, and the synthesis of steroid hormones. There are both exogenous and endogenous sources of cholesterol The average Ameπcan consumes about 450 mg of cholesterol each day and produces an additional 500 to 1,000 mg m the liver and other tissues Another source is the 500 to 1.000 mg of biliary cholesterol that is secreted into the intestine daily; about 50 percent is reabsorbed (enterohepatic circulation) The rate-limiting enzyme in endogenous cholesterol synthesis is 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase Tπglyceπdes. which are nonpolar pids consisting of a glycerol backbone and three fatty acids of varying length and degrees of saturation, are used for storage in adipose tissue and for energy. Lipoproteins are classified into groups based upon size, density, electrophoretic mobility, and hpid and protein composition Very low density lipoproteins (VLDL) are large, tπglyceπde-πch lipoproteins that are synthesized and secreted by hepatocytes. VLDL interacts with lipoprotein pase in capillary endothehum, and the core tπglyceπdes are hydrolyzed to provide fatty acids to adipose and muscle tissue. About half of the catabohzed VLDL particles are taken up by hepatic LDL receptors and the other half remain in plasma, becoming intermediate-density lipoprotein (LDL). IDL is enπched in cholesteryl esters relative to tπglyceπdes and is gradually converted by hepatic tπglyceπde hpase to the smaller, denser, cholesterol ester-πch LDL. As LDL is converted to LDL, apo poprotein E becomes detached, and only one apohpoprotein remains, apo B-100. LDL normally carπes about 75 percent of the circulating cholesterol. Cellular LDL uptake is mediated by a glycoprotem receptor molecule that binds to apo B-100. Approximately 70 percent of LDL is cleared by receptor uptake, and the remainder is removed by a scavenger cell pathway using nonreceptor mechanisms. The LDL receptors span the thickness of the cell's plasma membrane and are clustered in specialized regions where the cell membrane is indented to form craters called coated pits. These pits invaginate to form coated vesicles, where LDL is separated from the receptor and delivered to a lysosome so that digestive enzymes can expose the cholesteryl ester and cleave the ester bond to form free cholesterol. The receptor is recycled to the cell surface. As free cholesterol liberated from LDL accumulates within cells, there are three important metabolic consequences. First, there is a decrease in the synthesis of HMG-CoA reductase. the enzyme that controls the rate of de novo cholesterol biosynthesis by the cell. Second, there is activation of the enzyme acyl cholesterol acyltransferase (ACAT), which esteπfies free cholesterol into cholesterol ester, the cell's storage form of cholesterol. Third, accumulation of cholesterol suppresses the cell's synthesis of new LDL receptors. This feedback mechanism reduces the cell's uptake of LDL from the circulation. Lipoproteins play a central role in atherosclerosis. This association with the most common cause of death in the developed world defines the pπncipal clinical importance of the hyperhpoproteinemias. Individuals with an elevated cholesterol level are at higher πsk for atherosclerosis. Multiple lines of evidence, including epidemiological, autopsy, animal studies and clinical tπals, have established that LDL is atherosclerogenic and that the higher the LDL level, the greater the πsk of atherosclerosis and its clinical manifestations. A certain degree of LDL elevation appears to be a necessary factor in the development of atherosclerosis, although the process is modified by many other factors (e.g., blood pressure, tobacco use, blood glucose level, antioxidant level, and clotting factors). Acute pancreatitis is another major clinical manifestation of dyshpoproteinemia. It is associated with chylomicronemia and elevated VLDL levels. Most patients with acute pancreatitis have tπglyceπde levels above 2,000 mg/dL, but a 1983 NTH consensus development conference recommended that prophylactic treatment of hypertπglyceπdemia should begin when fasting levels exceed 500 mg/dL. The mechanism by which chylomicronemia and elevated VLDL levels cause pancreatitis is unclear. Pancreatic hpase may act on tπglyceπdes in pancreatic capillaπes, resulting in the formation of toxic fatty acids that cause inflammation. Abundant evidence indicates that treatment of hyperhpoproteinemia will diminish or prevent atherosclerotic complications. In addition to a diet that maintains a normal body weight and minimizes concentrations of lipids in plasma, therapeutic agents that lower plasma concentrations of lipoproteins, either by diminishing the production of lipoproteins or by enhancing the efficiency of their removal from plasma, are clinically important. The most promising class of drugs currently available for the treatment of hyperhpoproteinemia or hypercholesterolemia acts by inhibiting HMG-CoA reductase, the rate- hmiting enzyme in endogenous cholesterol synthesis. Drugs of this class competitively inhibit the activity of the enzyme. Eventually, this inhibition leads to a decrease in the endogenous synthesis of cholesterol and by normal homeostatic mechanisms, plasma cholesterol is taken up by LDL receptors to restore the intracellular cholesterol balance. Through both the release of precursors of LDL and receptor-mediated LDL uptake from the serum, liver cells play a cπtical role in maintaining serum cholesterol homeostasis. In both man and animal models, an inverse correlation appears to exist between liver LDL receptor expression levels and LDL-associated serum cholesterol levels. In general, higher hepatocyte LDL receptor numbers result in lower LDL-associated serum cholesterol levels. Cholesterol released into hepatocytes can be stored as cholesteryl esters, converted into bile acids and released into the bile duct, or it can enter into an oxycholesterol pool. It is this oxycholesterol pool that is believed to be involved in end product repression of both the genes of the LDL receptor and enzymes involved in the cholesterol synthetic pathway. Transcπption of the LDL receptor gene is known to be repressed when cells have an excess supply of cholesterol, probably in the form of oxycholesterol. A DNA sequence in the LDL receptor promoter region, known as the sterol response element (SRE), appears to confer this sterol end product repression. This element has been extensively investigated (Brown, Goldstein and Russell, U.S. Patents 4,745,060 and 4,935,363). The SRE can be inserted into genes that normally do not respond to cholesterol, conferπng sterol end product repression of the chimeπc gene. The exact mechanism of the repression is not understood. Brown and Goldstein have disclosed methods for employing the SRE in a screen for drugs capable of stimulating cells to synthesize LDL receptors (U S. Patent 4,935,363). It would be most desirable if the synthesis of LDL receptors could be upregulated at the level of gene expression The upregulation of LDL receptor synthesis at this level offers the promise of resetting the level of serum cholesterol at a lower, and clinically more desirable, level. Presently, however, there are no cholesterol loweπng drugs that are known to operate at the level of gene expression The present invention descπbes methods and compounds that act to inhibit directly or indirectly the repression of the LDL receptor gene, resulting in induction of the LDL receptor on the surface of liver cells, facilitating LDL uptake, bile acid synthesis and secretion to remove cholesterol metabolites and hence the loweπng of LDL-associated serum cholesterol levels. A number of human diseases stem from processes of uncontrolled or abnormal cellular proliferation. Most prevalent among these is cancer, a geneπc name for a wide range of cellular malignancies characteπzed by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize These neoplastic malignancies affect, with vaπous degrees of prevalence, every tissue and organ in the body. A multitude of therapeutic agents have been developed over the past few decades for the treatment of vaπous types of cancer. The most commonly used types of anticancer agents include: DNA-alkylating agents (e.g., cyclophosphamide, lfosfarmde), antimetabohtes (e.g., methotrexate, a folate antagonist, and 5-fluorouracιl, a pynmidme antagonist), microtubule disruptors (e.g., vincπstine, vinblastine, pachtaxel), DNA intercalators (e.g., doxorubicin, daunomycin, cisplatin), and hormone therapy (e.g., tamoxifen, flutamide). The ideal antmeoplastic drug would kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells. It would also retain its efficacy against malignant cells even after prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess an ideal profile. Most possess very narrow therapeutic indexes, and in practically every instance cancerous cells exposed to slightly sublethal concentrations of a chemotherapeutic agent will develop resistance to such an agent, and quite often cross-resistance to several other antmeoplastic agents. Psoπasis, a common chronic skin disease characteπzed by the presence of dry scales and plaques, is generally thought to be the result of abnormal cell proliferation. The disease results from hyperprohferation of the epidermis and incomplete differentiation of keratmocytes. Psoriasis often involves the scalp, elbows, knees, back, buttocks, nails, eyebrows, and genital regions, and may range in seventy from mild to extremely debilitating, resulting in psoπatic arthπtis, pustular psoπasis, and exfohative psoπatic dermatitis. No therapeutic cure exists for psoπasis Milder cases are often treated with topical corticosteroids, but more severe cases may be treated with antipro ferative agents, such as the antimetabo te methotrexate, the DNA synthesis inhibitor hydroxyurea, and the microtubule disrupter colchicine. Other diseases associated with an abnormally high level of cellular proliferation include restenosis, where vascular smooth muscle cells are involved, inflammatory disease states, where endothehal cells, inflammatory cells and glomerular cells are involved, myocardial infarction, where heart muscle cells are involved, glomerular nephπtis, where kidney cells are involved, transplant rejection, where endothehal cells are involved, infectious diseases such as HIV infection and malaπa, where certain immune cells and/or other infected cells are involved, and the like. Infectious and parasitic agents per se (e.g. bacteπa, trypanosomes, fungi, etc) are also subject to selective prohferative control using the subject compositions and compounds. Accordingly, it is one object of the present invention to provide compounds which directly or indirectly upregulate LDL receptor synthesis at the level of gene expression and are useful in the treatment of hypercholesterolemia or hyperhpoproteinemia. A further object of the present invention is to provide therapeutic compositions for treating said conditions A further object of the invention is to provide therapeutic compositions for treating pancreatitis. Still further objects are to provide methods for upregulatmg LDL receptor synthesis, for loweπng serum LDL cholesterol levels, and for preventing and treating atherosclerosis. A further object of the present invention is to provide compounds which directly or indirectly are toxic to actively dividing cells and are useful in the treatment of cancer, viral and bacteπal infections, vascular restenosis, inflammatory diseases, autoimmune diseases, and psoriasis. A further object of the present invention is to provide therapeutic compositions for treating said conditions. Still further objects are to provide methods for killing actively proliferating cells, such as cancerous, bacteπal, or epithelial cells, and treating all types of cancers, infections, inflammatory, and generally prohferative conditions. A further object is to provide methods for treating other medical conditions characteπzed by the presence of rapidly proliferating cells, such as psoπasis and other skin disorders. Other objects, features and advantages will become apparent to those skilled in the art from the following descπption and claims. SUMMARY OF THE INVENTION The invention provides novel arylsulfonani de phosphate compounds, as well as methods and compositions relating to novel arylsulfonanihde phosphates and their use as pharmacologically active agents. The compounds and compositions find use as pharmacological agents in the treatment of disease states, particularly hypercholesterolemia, atherosclerosis, cancer, bacteπal infections, and psoπasis, or as lead compounds for the development of such agents. The compounds of the invention have the formula: or a pharmaceutically acceptable salt thereof. In the above formula, the symbol R 1 represents a hydrogen, (C,-C 6 )alkyl or (C r C 6 )heteroalkyl. The symbols R 2 and R 3 are each independently hydrogen, halogen, (C r C g )alkyl, (C,-C 8 )heteroalkyl, -OR 11 or -NR π R 12 , in which the symbols R π and R 12 each independently represent hydrogen, (C,-C 8 )alkyl or (C,-C 8 )heteroalkyl. Alternatively, R 2 and R 3 , when attached to adjacent carbon atoms, can be linked together to form a fused 5-, 6- or 7- membered πng. The symbols R 4 and R 5 each independently represent hydrogen, (C,-C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, heteroaryl, aryl(C r C 4 )alkyl, aryl(C,-C 4 )heteroalkyl, heteroaryl(C,- C 4 )alkyl and heteroary ^-C heteroalkyl. Optionally, R 4 and R 5 are linked together to form a 5-, 6- or 7-membered πng. Additionally, R 4 can also represent a single bond to the phenyl πng beaπng the phosphoryl group. When R 4 is a single bond to the phenyl πng, R 5 is hydrogen, (C r C 8 )alkyl, (C,-C 8 )heteroalkyl, aryl, heteroaryl, aryl(C,-C 4 )alkyl, aryl(C r C 4 )heteroalkyl, heteroaryl(C r C 4 )alkyl or heteroaryl (C r C 4 )heteroalkyl. The symbol Ar represents a substituted aryl group selected from the group of: in which X 1 and X 2 are each independently F, Cl or Br. The methods of the present invention use pharmaceutical compositions containing compounds of the foregoing descπption of the general Formula I for the treatment of pathology such as cancer, bacteπal infections, psoπasis, hypercholesterolemia, atherosclerosis, pancreatitis, and hyperhpoproteinemia. Bπefly, the inventions involve administeπng to a patient an effective formulation of one or more of the subject compositions. DETAILED DESCRIPTION OF THE INVENTION Definitions The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multi- radicals, having the number of carbon atoms designated (i.e. C,-C 10 means one to ten carbons). Examples of saturated hydrocarbon radicals include groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or tπple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-ιsopentenyl, 2-(butadιenyl), 2,4-pentadιenyl, 3-(l,4-pentadιenyl), ethynyl, 1- and 3- propynyl, 3-butynyl, and the higher homologs and isomers. The term "alkyl," unless otherwise noted, is also meant to include those deπvatives of alkyl defined in more detail below as "cycloalkyl" and "alkylene." The term "alkylene" by itself or as part of another substituent means a divalent radical deπved from an alkane, as exemplified by -CH ^ CH^ILCH,-. Typically, an alkyl group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being prefeπed m the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term "alkoxy," employed alone or in combination with other terms means, unless otherwise stated, an alkyl group, as defined above, connected to the remainder of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy and the higher homologs and isomers. The term "heteroalkyl," by itself or combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any inteπor position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include -CH,-CH,-O-CH-, -CH 2 -CH 2 -NH-CH 3 , -CH 2 -CH 2 -N(CH 3 )-CH 3 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 -S(0)-CH 3 , -CH 2 -CH 2 -S(0) 2 -CH 3 , -CH=CH-0-CH 3 , -Sι(CH 3 )„ -CH 2 -CH=N-OCH 3 , and -CH=CH-N(CH 3 )-CH 3 Up to two heteroatoms may be consecutive, such as, for example, -CH-,-NH-OCH 3 and -CH 2 -0-Sι(CH 3 ) 3 . Also included in the term heteroalkyl" are those radicals descπbed in more detail below as "heteroalkylene' and "heterocycloalkyl " The term "heteroalkylene" by itself or as part of another substituent means a divalent radical deπved from heteroalkyl, as exemplified by -CH 2 -CH 2 -S-CH,CH 2 - and - CH 2 -S-CH 2 -CH 2 -NH-CT - For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini Still further, for alkylene and heteroalkylene linking groups, as well as all other linking groups descπbed herein, no specific oπentation of the linking group is implied The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like Examples of heterocycloalkyl include l-(l,2,5,6-tetrahydropyπdyl), 1-pιpendmyl, 2- pipeπdinyl, 3-pιpeπdιnyl, 4-morpholιnyl, 3-morpholιnyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothιen-2-yl, tetrahydrothιen-3-yl, 1-pιperazιnyl, 2-pιperazιnyl, and the like The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluoπne, chloπne, bromine, or iodine atom Additionally, terms such as "fluoroalkyl," are meant to include monofluoroalkyl and polyfluoroalkyl The term "aryl," employed alone or in combination with other terms (e g , aryloxy, arylthioxy, arylalkyl) means, unless otherwise stated, an aromatic substituent which can be a single πng or multiple πngs (up to three πngs) which are fused together or linked covalently The πngs may each contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatermzed The aryl groups that contain heteroatoms may be referred to as "heteroaryl" and can be attached to the remainder of the molecule through a carbon atom or a heteroatom Non- hmitmg examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-bιphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-ιmιdazolyl, 4-ιmιdazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-ιsoxazolyl, 4-ιsoxazolyl, 5-ιsoxazolyl, 2-thιazolyl, 4-thιazolyl, 5-thιazolyl, 2-furyl, 3-furyl, 2-thιenyl, 3-thιenyl, 2-pyπdyl, 3-pyπdyl, 4-pyπdyl, 2-pyπmιdyl, 4-pyπmιdyl, 5-benzothιazolyl, puπnyl, 2-benzιmιdazolyl, 5-ιndolyl, 1-ιsoquιnolyl, 5-ιsoquιnolyl, 2-quιnoxalιnyl, 5-quιnoxalιnyl, 3-quιnolyl, and 6-quιnolyl Substituents for each of the above noted aryl πng systems are selected from the group of acceptable substituents descπbed below The terms "arylalkyl" and "arylheteroalkyl" are meant to include those radicals in which an aryl group is attached to an alkyl group (e g , benzyl, phenethyl, pyπdylmethyl and the like) or a heteroalkyl group (e g , phenoxymethyl, 2-pyπdyloxymethyl, l-naphthyloxy-3- propyl, and the like) The arylalkyl and arylheteroalkyl groups will typically contain from 1 to 3 aryl moieties attached to the alkyl or heteroalkyl portion by a covalent bond or by fusing the πng to, for example, a cycloalkyl or heterocycloalkyl group. For arylheteroalkyl groups, a heteroatom can occupy the position at which the group is attached to the remainder of the molecule. For example, the term "arylheteroalkyl" is meant to include benzyloxy, 2- phenylethoxy, phenethylamine, and the like Each of the above terms (e.g , "alkyl," "heteroalkyl" and "aryl") are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below. Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a vaπety of groups selected from: -OR', =O, =NR\ =N-OR\ -NR'R", -SR', -halogen, -SιR'R"R" \ -OC(0)R', - CO 2 R\ -CONR'R", -OC(0)NR'R", -NR"C(0)R', -NR"C(O) 2 R', -NH-C(NH 2 )=NH, - NR'C(NH,)=NH, -NH-C(NH 2 )=NR', -S(0)R', -S(0) 2 R', -S(O) 2 NR'R", -CN and -N0 2 in a number ranging from zero to (2N+1), where N is the total number of carbon atoms in such radical. R', R" and R'" each independently refer to hydrogen, unsubstιtuted(C r C 8 )alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C C 4 )alkyl groups. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered πng. For example, -NR'R" is meant to include 1-pyrrohdmyl and 4-morphohnyl. Similarly, substituents for the aryl groups are vaπed and are selected from: -halogen, -OR', -OC(O)R\ -NR'R", -SR', -R\ -CN, -NO 2 , -CO 2 R', -CONR'R", -OC(0)NR'R", -NR"C(O)R\ -NR"C(0) 2 R', -NH-C(NH 2 )=NH, -NR'C(NH 2 )=NH, -NH-C(NH 2 )=NR\ -S(O)R', -S(0) 2 R', -S(0) 2 NR'R", -N 3 , -CH(Ph) 2 , perfluoro(C r C 4 )alkoxy, and perfluoro(C 1 -C 4 )alkyl, in a number ranging from zero to the total number of open valences on the aromatic πng system; and where R' and R" are independently selected from hydrogen, (C r C 8 )alkyl and heteroalkyl, unsubstituted aryl, (unsubstituted aryl)-(C,- C 4 )alkyl, and (unsubstituted aryl)oxy-(C,-C 4 )alkyl. Two of the substituents on adjacent atoms of the aryl nng may optionally be replaced with a substituent of the formula -T-C(0)-(CH 2 ) q -U-, wherein T and U are independently -NH-, -0-, -CH 2 - or a single bond, and q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl πng may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CH 2 -, -0-, -NH-, -S-, -S(O)-, -S(O),-, -S(0) 2 NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new πng so formed may optionally be replaced with a double bond Alternatively, two of the substituents on adjacent atoms of the aryl πng may optionally be replaced with a substituent of the formula -(CH 2 ) S -X-(CH,),-, where s and t are independently integers of from 0 to 3, and X is -0-, -NR'-, -S-, -S(O)-, -S(0) 2 -, or -S(0) 2 NR'- The substituent R' in -NR'- and -S(0) 2 NR'- is selected from hydrogen or unsubstituted (C,-C 6 )alkyl As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si). The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds descπbed herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or m a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammo, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or m a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those deπved from inorganic acids like hydrochloric, hydrobromic, nitπc, carbonic, monohydrogencarbomc, phosphoπc, monohydrogenphosphoπc, dihydrogenphosphoπc, sulfuπc, monohydrogensulfuπc, hydπodic, or phosphorous acids and the like, as well as the salts deπved from relatively nontoxic organic acids like acetic, propiomc, isobutyπc, oxalic, maleic, malonic, benzoic, succimc, subeπc, fumaπc, mandehc, phthahc, benzenesulfomc, p-tolylsulfomc, citπc, tartaπc, methanesulfonic, and the like. Also included are salts of ammo acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoπc acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the vaπous salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention. In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds descπbed herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound of formula I Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme. Certain compounds of the present invention can exist m unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention. Certain compounds of the present invention possess asymmetπc carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometπc isomers and individual isomers are all intended to be encompassed within the scope of the present invention The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tπtium ( 3 H), ιodme-125 ( 125 I) or carbon-14 ( 14 C). All isotopic vaπations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention General The compounds descπbed herein are related to compounds provided in PCT publications WO 97/30677 and WO 98/05315. More particularly, compounds are now descπbed having an attached phosphate, phosphate salt, or phosphate ester group. These arylsulfonanihde phosphates are less lipophihc that the coπespondmg arylsulfonanihde phenols and are expected to reduce brain concentrations of the phenol when administered as a bolus intravenously Without intending to be bound by any particular theory, it was believed that the compounds would be readily hydrolyzed in vivo to provide the phenol as the active species. However, the compounds of the present invention have demonstrated surpπsing stability in cell culture media, dosing solution, and mouse plasma, yet provide a level of efficacy against a tumor model equivalent to the parent phenol (non-phosporylated compound) which appears to be present in an amount of only about 4-10% (based on the administered arylsulfonanihde phosphate) Additionally, the arylsulfonanihde phosphates provide a bulk stability, or improved shelf-life, relative to the parent phenols Embodiments of the Invention The present invention provides novel arylsulfonanihde phosphate deπvatives having the formula: in which the symbol R 1 represents hydrogen, (C j -C alkyl or (C,-C 6 )heteroalkyl, preferably hydrogen. The symbols R 2 and R 3 are each independently hydrogen, halogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, -OR" or -NR π R 12 , in which R 11 and R 12 are each independently hydrogen, (C r C 8 )alkyl or (C,-C 8 )heteroalkyl. Additionally, when R 2 and R 3 are attached to adjacent carbon atoms, they can be linked together to form a fused 5-, 6- or 7-membered πng. In preferred embodiments, R 2 and R 3 occupy positions on the phenyl πng that are meta and/or para to the sulfonanihde nitrogen. More preferably, R 2 represents hydrogen, (C r C 3 )alkyl or (C r C 3 )alkoxy. In other preferred embodiments, R 3 represents hydrogen, (C,-C 3 )alkyl, -OR 11 or -NR U R 12 , wherein R" and R 12 are each independently hydrogen, (C r C 3 )alkyl or (C,- C 3 )heteroalkyl The symbols R 4 and R 5 are each independently hydrogen, (C r C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, heteroaryl, aryl(C,-C 4 )alkyl, aryl(C r C 4 )heteroalkyl, heteroaryl(C C 4 )alkyl or heteroary C j -C heteroalkyl. In one group of embodiments, R 4 and R 5 are optionally linked together to form a 5-, 6- or 7-membered πng. Alternatively, R 4 represents a single bond to the phenyl πng beaπng the phosphoryl group and R 5 is hydrogen, (C,-C 8 )alkyl, (C j -C^heteroalkyl, aryl, heteroaryl, aryl(C j -C 4 )alkyl, aryl(C,-C 4 )heteroalkyl, heteroaryl (C,- C 4 )alkyl and heteroaryKC j -CJheteroalkyl. The symbol Ar is a substituted aryl group selected from: in which X 1 and X 2 are each independently selected from F, Cl and Br. In one group of preferred embodiments, Ar is pentafluorophenyl. In another group of preferred embodiments, Ar is 2,3,4,5-tetrafluorophenyl. In yet another group of preferred embodiments, Ar is 3,4,5-tπmethoxyphenyl. In still another group of preferred embodiments, Ar is 3-methoxy-4,5-methylenedιoxyphenyl. In addition to the generally preferred substituents provided above, a number of particular formulae are also preferred. One preferred group of compounds are represented by the formula: In this group of embodiments, R'-R 5 can be any of the groups descπbed above. Preferably, R 1 is hydrogen. R 2 is preferably hydrogen, (C,-C 3 )alkyl or (C,-C 3 )alkoxy, and R 3 is preferably hydrogen, (C,-C 3 )alkyl, -OR" or -NR n R 12 , wherein R 11 and R 12 are each independently hydrogen, (C r C 3 )alkyl or (C j -C 3 )heteroalkyl. In another group of preferred embodiments, the compounds have the formula: In this group of embodiments, as with those immediately above, R'-R 5 can be any of the groups descπbed for formula I. Preferably, R 1 is hydrogen, R 2 is hydrogen, (C r C 3 )alkyl or (C,-C 3 )alkoxy, and R 3 is hydrogen, ( -C^alkyl, -OR 11 or -NR"R 12 , wherein R" and R 12 are each independently hydrogen, (C,-C 3 )alkyl or (C j -C 3 )heteroalkyl. In the most preferred embodiments, R 1 is hydrogen, R 2 is hydrogen and R 3 is methoxy, methyl, dimethylamino or hydroxy. R 4 and R 5 are preferably hydrogen, (C r C 3 )alkyl or aryl. In yet another group of preferred embodiments, the compounds have the formula: In this group of embodiments, the preferred substituents are the same as those descπbed for formula lb. In still another group of preferred embodiments, the compounds have the formula: In this group of embodiments, the preferred substituents are the same as those descπbed for formula lb In still another group of preferred embodiments, the compounds have the general formula I in which R 2 and R 3 are combined to form a fused 5-member πng. Preferred compounds in this group of embodiments are exemplified by the compounds: Synthesis Compounds of the present invention can be prepared using certain intermediates and methods descπbed in WO 97/30677 and WO 98/05315. In one group of embodiments, arylsulfonamidophenols can be prepared as descπbed, and the phenolic hydroxy group can then be phosphorylated using reagents such as diethylphosphorylchloπde or dimethylphosphorylchloπde. Additional compounds can be prepared via ester exchange or saponification. Still other phosphorylation procedures useful in prepaπng the present compounds are descπbed in Silverberg, et al, Tetrahedron Lett. 37(6):771-774 (1996), Saulnier, et al, Bworg. Med. Chem. Lett. 4:2567-2572 (1994), and U.S. Patent No. 5,561,122, the disclosures of each being incorporated herein by reference. The compounds used as initial starting mateπals in this invention may be purchased from commercial sources or alternatively are readily synthesized by standard procedures which are well know to those of ordinary skill in the art. Some of the compounds of Formula I may exist as stereoisomers, and the invention includes all active stereoisomeπc forms of these compounds In the case of optically active isomers, such compounds may be obtained from corresponding optically active precursors using the procedures descπbed above or by resolving racemic mixtures. The resolution may be earned out using vaπous techniques such as chromatography, repeated recrystal zation of deπved asymmetπc salts, or deπvatization, which techniques are well known to those of ordinary skill in the art. The compounds of the invention may be labeled in a vaπety of ways. For example, the compounds may contain radioactive isotopes such as, for example, 3 H (tπtium) and 14 C (carbon-14). Similarly, the compounds may be advantageously joined, covalently or noncovalently, directly or through a linker molecule, to a wide vaπety of other compounds, which may provide pro-drugs or function as earners, labels, adjuvents, coactivators, stabilizers, etc. Such labeled and joined compounds are contemplated within the present invention Analysis of compounds Representative compounds and compositions were demonstrated to have pharmacological activity in in vitro and in vivo assays, e.g., they are capable of specifically modulating a cellular physiology to reduce an associated pathology or provide or enhance a prophylaxis. Certain preferred compounds and compositions are capable of specifically regulating LDL receptor gene expression. Compounds may be evaluated in vitro for their ability to increase LDL receptor expression using western-blot analysis, for example, as descnbed in Tarn et al. (J. Bwl Chem. 1991, 266, 16764). Established animal models to evaluate hypocholesterolemic effects of compounds are known in the art. For example, compounds disclosed herein are shown to lower cholesterol levels in hamsters fed a high- cholesterol diet, using a protocol similar to that descπbed in Spady et al. ( J. Clin. Invest 1988, 81, 300), Evans et al. (J. Lψid Res. 1994, 35, 1634), and Lin et al (J Med Chem. 1995, 38, 277). Certain preferred compounds and compositions display specific toxicity to vaπous types of cells. Certain compounds and compositions of the present invention exert their cytotoxic effects by interacting with cellular tubulin. For certain preferred compounds and compositions of the present invention, that interaction is covalent and irreversible. Compounds and compositions may be evaluated in vitro for their ability to inhibit cell growth, for example, as described in Ahmed et al. (J. Immunol. Methods 1994, 170, 211) Established animal models to evaluate antiprohferative effects of compounds are known in the art. For example, compounds can be evaluated for their ability to inhibit the growth of human tumors grafted into immunodeficient mice using methodology similar to that descπbed by Rygaard and Povlsen (Acϊa Pathol Microbiol. Scand. 1969, 77. 758) and Giovanella and Fogh (Adv. Cancer Res 1985, 44, 69) Formulation and administration of compounds and pharmaceutical compositions The invention provides methods of using the subject compounds and compositions to treat disease or provide medicinal prophylaxis, to upregulate LDL receptor gene expression in a cell, to reduce blood cholesterol concentration in a host, to slow down and/or reduce the growth of tumors, etc. These methods generally involve contacting the cell with or admimsteπng to the host an effective amount of the subject compounds or pharmaceutically acceptable compositions. The compositions and compounds of the invention and the pharmaceutically acceptable salts thereof can be administered in any effective way such as via oral, parenteral or topical routes. Generally, the compounds are administered in dosages ranging from about 2 mg up to about 2,000 mg per day, although vaπations will necessaπly occur depending on the disease target, the patient, and the route of administration. Preferred dosages are administered orally in the range of about 0.05 mg/kg to about 20 mg/kg, more preferably in the range of about 0.05 mg/kg to about 2 mg/kg, most preferably in the range of about 0.05 mg/kg to about 0.2 mg per kg of body weight per day In one embodiment, the invention provides the subject compounds combined with a pharmaceutically acceptable excipient such as steπle saline or other medium, water, gelatin, an oil, etc. to form pharmaceutically acceptable compositions. The compositions and/or compounds may be administered alone or in combination with any convenient earner, diluent, etc. and such administration may be provided in single or multiple dosages. Useful earners include solid, semi-solid or liquid media including water and non-toxic organic solvents In another embodiment, the invention provides the subject compounds in the form of a pro-drug, which can be metabo cally converted to the subject compound by the recipient host. A wide vaπety of pro-drug formulations are known in the art. The compositions may be provided m any convenient form including tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, suppositories, etc. As such the compositions, in pharmaceutically acceptable dosage units or m bulk, may be incorporated into a wide vaπety of containers. For example, dosage units may be included in a vaπety of containers including capsules, pills, etc The compositions may be advantageously combined and/or used in combination with other hypocholesterolemic or antipro ferative therapeutic or prophylactic agents, different from the subject compounds. In many instances, administration in conjunction with the subject compositions enhances the efficacy of such agents. Examplary antiprohferative agents include cyclophosphamide, methotrexate, adπamycin, cisplatin, daunomycin, vincπstine, vinblasune, vinarelbine, pachtaxel. docetaxel, tamoxifen, flutamide, hydroxyurea. and mixtures thereof. Exemplary hypocholesterolemic and/or hypohpemic agents include: bile acid sequestrants such as quaternary amines (e.g. cholestyramine and colestipol); nicotimc acid and its denvatives; HMG-CoA reductase inhibitors such as mevastatin, pravastatin, and simvastatin; gemfibrozil and other fibnc acids, such as gemfibrozil, clofibrate, fenofibrate, benzafibrate and cipofibrate; probucol, raloxifene and its deπvatives; and mixtures thereof. The compounds and compositions also find use in a vaπety of in vitro and in vivo assays, including diagnostic assays. For example, vanous allotypic LDL receptor gene expression processes may be distinguished in sensitivity assays with the subject compounds and compositions, or panels thereof. In certain assays and in in vivo distnbution studies, it is desirable to used labeled versions of the subject compounds and compositions, e g. radioligand displacement assays. Accordingly, the invention provides the subject compounds and compositions compπsing a detectable label, which may be spectroscopic (e.g. fluorescent), radioactive, etc The following examples are offered by way of illustration and not by way of limitation. EXAMPLES 'H-NMR spectra were recorded on a Vanan Gemini 400 MHz NMR spectrometer. Significant peaks are tabulated in the order: number of protons, multiplicity (s, singlet; d, doublet; t, tπplet; q, quartet; m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz. Electron Ionization (El) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses) Preparation of Synthetic Intermediates The majoπty of the starting mateπals for the synthesis of the examples of the present invention are available from commercial sources or are known compounds descnbed in the published literature. Literature references of general utility to the following examples include: 1) Organic Svntheses, Coll. Vol VII; 1990, Jeremiah P. Freeman, ed., John Wiley & Sons, 508-511. 2) Robson, P.. Smith, T.A., Stephens, R., Tatlow, J , J. Chem. Soc, 1963, 3692-3703. 3) Synthesis of Fluoroorgamc Compounds, 1985, Knunyants, I. and Yakobson, G., eds., Spπnger-Verlag,190. The synthesis of a selected group of starting matenals is exemplified as follows in Examples A-K: Example A 3,5-Dichloro-2,4,6-trifluorophenylsulfonyl chloride. l,3-Dichloro-2,4,6-tnfluorobenzene (5.0 g, 25 mmol) and chlorosulfonic acid (10.0 mL, 150 mmol) were mixed at ambient temperature under a nitrogen atmosphere and the reaction was heated at 80 °C for 24 h. The mixture was then allowed to cool to ambient temperature and was poured onto 12 g of crushed ice. The product was extracted with diethyl ether, dned over MgS0 4 , and the solvent was evaporated to produce 4.9 g of the title compound, which was used without further purification. MS (El): 300 (30, M + ), 298 (28), 263 (100), 199 (80). Examples B and C 5-Bromo-2,3,4-trifluorophenylsulfonyl chloride (Example B) and 2- Bromo-3,4,5-trifluorophenylsulfonyl chloride (Example C). The title compounds were obtained as a mixture from l-bromo-2,3,4-tπfluorobenzene by a method similar to that used in Example A. Example D 2-Bromo-3,4,5,6-tetrafluorophenylsuIfonyl chloride. l-Bromo-2,3,4,5-tetrafluorobenzene (5 0 g, 21.8 mmol) was mixed at ambient temperature with 20% fuming sulfuπc acid (20 mL) The mixture was heated at 40 °C for 3 h and at 110 °C for 2 h. The reaction mixture was allowed to cool to ambient temperature and poured onto 12 g of crushed ice. The mixture was acidified dropwise with concentrated HCl (2 mL) until a solid, consisting mostly of 2-bromo-3,4,5,6-tetrafluorophenylsulfonιc acid was formed. The solid was filtered, washed with 12N HCl, and dned under high vacuum to afford 5.3 g of 2- bromo-3,4,5,6-tetrafluorophenylsulfonιc acid as a white hygroscopic solid that was used without further punfication To the sulfonic acid (3.0 g, 9.7 mmol) was then added phosphorous pentachloπde (8.0 g, 384 mmol) in small portions, at ambient temperature (Caution: exothermic reaction with significant evolution of HCl). The reaction was allowed to stir for 20 minutes after the final addition of phosphorous pentachlonde The reaction mixture was then poured onto crushed ice and the white solid that formed was filtered and dned to afford 2.8 g of the title compound, which was used without further punfication MS (El): 328 (30, M + ), 293 (70), 229 (30), 148 (100). Example E 3-Bromo-2,4,5,6-tetrafluorophenylsulfonyl chloride. The title compound was synthesized from l-bromo-2,3,4,6-tetrafluorobenzene by a method similar to that used in Example D. MS (El). 328 (20, M + ), 293 (70), 229 (50), 148 (100). Example F l-Bromo-3,4,5,6-tetrafluoro-2-[(3-hydroxy-4-methoxyphenyl)amino- sulfonyl]benzene. The title compound was prepared in a manner similar to that descπbed in Example 6 of WO 97/30677, beginning with 3-hydroxy-4-methoxyanιhne and 2-bromo- 3,4,5,6-tetrafluorophenylsulfonyl chloride (Example D, above). 'H-NMR (CDC1 3 ): δ 7.28 (br s, 1H), 6.69 (m, 3H), 5.72 (s, 1H), 3.82 (s, 3H). MS (El): 431 (20), 429 (20), 138 (100). Anal, calcd. for C 13 H 8 BrF N0 4 S: C, 36.30; H, 1.87; N, 3.26; S, 7.45. Found: C, 36.20; H, 1.90; N, 3.31; S, 7.39. Example G l,3-Dichloro-2,4,6-trifluoro-5-[(3-hydroxy-4-methoxyphenyl)amino- sulfonyl] benzene. The title compound was prepared in a manner similar to that descnbed in Example 6 of WO 97/3-677, beginning with 3-hydroxy-4-methoxyanιlιne and 3,5-dichloro-2,4,6- tnfluorophenylsulfonyl chloride (Example A, above). 'H-NMR (CDC1 3 ): δ 6.88 (1H, br s), 6.7- 6.8 (3H, m), 5.66 (1H, s), 3.85 (3H, s). MS(EI): 402 (15, M + ), 401 (20), 138 (100). Anal. Calcd. for C 13 H 8 C1 2 F 3 N0 4 S: C, 38.83; H, 2.00; N, 3.48; S, 7.97. Found: C, 38.66; H, 1.97; N, 3.39; S, 7.86. Example H l-Bromo-2,3,4-trifluoro-5-[(3-hydroxy-4-methoxyphenyl)amino- sulfonyl]benzene. l-Bromo-2,3,4-tnfluoro-5-[(3-hydroxy-4-methoxyphenyl)amιnosulfonyl]benzene and l-Bromo-4,5,6-tnfluoro-2-[(3-hydroxy-4-methoxyphenyl)amιno-sulfonyl]benzene were prepared in a manner similar to that descnbed above, beginning with a mixture of 5-bromo-2,3,4- trifluorophenylsulfonyl chlonde (Example B) and 2-bromo-3,4,5-tπfluorophenylsulfonyl chloride (Example C) and 3-hydroxy-4-methoxyanιhne. The two isomenc compounds were separated by column chromatography (silica gel; ethyl acetate: hexanes, 1:4). 'H-NMR (CDC1 3 ): δ 7.79 (IH, m), 6.72-6.62 (4H, m), 5.65 (IH, s), 3.85 (3H, s). Example I 2,3,4,5-Tetrafluoro-l-[(3-hydroxy-4- methoxyphenyl)aminosulfonyl]benzene. The title compound was prepared via catalytic hydrogenation of the compound prepared in Example F above. Briefly, the starting material was in methanol and placed in a closed vessel. A catalytic amount of 10% Pd/charcoal was added and the mixture was hydrogenated at 60 psi H, for 4 h. The resulting mixture was filtered through celite, the solvent was evaporated and the residue was purified by chromatography (silica; EtOAc/Hexane, 1:4) to yield the title compound. 'H-NMR (CDC1 3 ): δ 7.43 (IH, m), 6.80 (IH, br s), 6.73-6.60 (3H, m), 5.67 (IH, s), 3.84 (3H, s). MS(EI): 351 (20, M + ), 138 (100). Anal. Calcd. for C 13 H 9 F 4 N0 4 S: C, 44.45; H, 2.58; N, 3.99; S, 9.13. Found: C, 44.39; H, 2.59; N, 3.94; S, 9.24. Preparation of other intermediate benzenesulfonamidophenols are described in WO 97/30677 and WO 98/05315. For example, 2-hydroxy-l-methoxy-4-pentafluorophenyl- sulfonamidobenzene (Example 6, page 33); 3-hydroxy-l-pentafluorophenyl- sulfonamidobenzene (Example 9, page 34): 4-hydroxy-l-pentafluorophenyl- sulfonamidobenzene (Example 10, page 35); l,3-dimethoxy-2-hydroxy-5-pentafluoro- phenylsulfonamidobenzene (Example 27, page 45); and 3-hydroxy-5-methoxy-l- pentafluorophenyl-sulfonamidobenzene (Example 28, page 46) are described in each of the cited PCT publications. Example J 3,4,5-Trimethoxybenzenesulfonyl Chloride. 3,4,5-Tπmethoxybenzenesulfonyl chlonde was synthesized from 3,4,5- tπmethoxyanihne according to the procedure descπbed in G. Piffeπ and R. Monguzzi, Journal of Pharmaceutical Sciences, 1973, 62, 1393. In this procedure the aniline was dissolved m concentrated hydrochloπc acid and to the resulting mixture was added a solution of aqueous sodium nitnte at 0°C, the resulting mixture containing the desired diazonium salt was added at 5°C to a saturated solution of sulfur dioxide in glacial acetic acid containing substoichiometπc amount of cuprous chlonde. The mixture was stirred at ambient temperature for 3h, poured into cold water, and the product extracted with dichloromethane. The solvent was evaporated and the solid residue was recrystallized from hexanes. Example K l-[(3-Hydroxy-4-methoxyphenyl)aminosulfonyl]-3,4,5-trimethox benzene To a solution of 3,4,5-tπmethoxybenzenesulfonyl chlonde (500 mg, 1.88 mmol) m methanol (10 mL) was added 3-hydroxy-4-methoxyanιhne (523 mg, 3.76 mmol) at ambient temperature. After stirπng for 1 h, the reaction mixture was concentrated and the crude residue was puπfied by chromatography over silica to afford 430 mg (62%) of product as fine white needles, m.p. 145-146°C. 'H-NMR (CDC1 3 ): δ 9.74 (IH, s), 9.15 (IH, s), 6.98 (2H, s), 6.78 (IH, d, 7=8.8 Hz), 6.63 (IH, d, 7=2.6 Hz), 6.50 (IH, dd, 7=8.8, 2.6 Hz), 3.76 (6H, s), 3.70 (3H, s), 3.68 (3H, s). Anal. Calcd. for C l6 H 19 N,0 7 S: C, 52.03; H, 5.18; N, 3.79; S, 8.68. Found: C, 51.87; H, 5.28; N, 3.76; S, 8.77. Each of the phenols above, as well as the related members having different substitution patterns can be phosphorylated using known methods including the procedure descnbed in detail in Example 1. EXAMPLE 1 This example illustrates the phosphorylation of the 2-hydroxy-l-methoxy-4- (pentafluorophenylsulfonamιdo)benzene to produce 5-(pentafluorophenylsulfonamιdo)-2- methoxyphenyl phosphate. 5-(Pentafluorophenylsulfonamido)-2-methoxyphenyl phosphate 2-Hydroxy-l-methoxy-4-(pentafluorophenylsulfonamιdo)benzene, prepared as descnbed in WO 97/30677, (3.0 g, 8.2 mmol) and tetrazole (1.4 g, 19.7 mmol) were combined in 70 mL of dry THF and N,N-dnsopropyl dibenzylphosphoramidite (2.8 mL, 8.2 mmol) was added. The reaction mixture was stirred at room temperature for 4.0 hours. At this point, the reaction mixture was cooled to 0°C in an ice bath and 14% r-butyl peroxide (22 mL, 22.1 mmol) was slowly added. The reaction mixture was stirred for 0.5 hours, then 75 mL of a 10% NaS 2 0 3 solution was added and the resulting mixture was stirred at room temperature for an additional 0 5 hours. THF was removed in vacuo, and the aqueous portion was extracted with EtOAc. The organic extract was dned over anhydrous MgS0 4 and the solvent was removed to provide a crude colorless oil that was punfied by silica gel chromatography (3:7 EtOAc:hexanes as eluant). The product fractions were isolated and solvent was removed in vacuo to yield 3.9 g of a thick clear oil. 'H NMR (CDCl j ): δ 3.73 (s, 3H); 5.05 (t, 7=9.1 Hz, IH); 5.13 (s, 2H); 5.16 (s, 2H); 6.76 (d, 7=11.8 Hz, IH); 7.00 (d, 7=11.8 Hz, IH); 7.06 (s, IH); 7.31 (s, 10H) ES MS: (M- H)=628.1 The intermediate phosphate diester (3.5 g, 5 6 mmol) was dissolved in 50 mL of dry ethanol. This was quickly poured into a flask containing 1.0 g of 10% palladium on carbon. Then 4.5 g (55.6 mmol) of cyclohexadiene was added and the reaction was allowed to stir at room temperature under a hydrogen atmosphere overnight The palladium on carbon was removed by filtration through a layer of celite, and the solvent was removed in vacuo The crude mixture was punfied by reverse-phase HPLC. Removal of the solvents gave 1.13 g of the product phosphate as a white solid. EXAMPLE 2 Assessment of Biological Activity. . The ability of test compounds to arrest the growth of tumor cells m culture was evaluated using HeLa cells, denved from a human cervical adenocarcinoma, and obtained from the Amencan Type Culture Collection (ATCC, Rockville, MD). Cells were grown in culture in the usual way. Test compounds were dosed in tπphcate at concentrations ranging from 5 nM to 50 μM, and the cellular growth rate was calculated by harvesting the cells after 72 hours of treatment and measunng their metabolic activity using an Alamar Blue assay (Biosource International, Camanllo, CA). The degree of metabolic activity in the culture is proportional to the number of living cells. See, Ahmed et al., J. Immunol. Methods 1994, 170, 211. The change in growth rate for cells treated with test compounds was normalized to the growth of untreated cells and a plot of normalized cellular growth vs. compound concentration was made. The concentration at which 50% growth inhibition (GI50) occurred was determined using a curve fitting program. The following selected example displays potent cytotoxic activity in this assay. Compound GI50 (nM) Example 1 15 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been descπbed in some detail by way of illustration and example for purposes of claπty of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spiπt or scope of the appended claims.

Claims: WHAT IS CLAIMED IS: 1. A compound having the formula: or a pharmaceutically acceptable salt thereof, wherein R' is a member selected from the group consisting of hydrogen, (C r C 6 )alkyl and (C r C 6 )heteroalkyl; R 2 and R 3 are each independently selected from the group consisting of hydrogen, halogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, -OR" and -NR"R 12 , wherein R' 1 and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 8 )alkyl and (C,- C 8 )heteroalkyl; or R 2 and R 3 , when attached to adjacent carbon atoms, can be linked together to form a fused 5-, 6- or 7-membered ring; R 4 and R 5 are each independently selected from the group consisting of hydrogen, (C r C g )alkyl, (C r C 8 )heteroalkyl, aryl, heteroaryl, aryl(C,-C 4 )alkyl, aryl(C r C 4 )heteroalkyl, heteroaryl(C r C 4 )alkyl and heteroaryl(C r C 4 )heteroalkyl, and are optionally linked together to form a 5-, 6- or 7-membered ring; or R 4 represents a single bond to the phenyl ring bearing the phosphoryl group and R 5 is selected from the group consisting of hydrogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, aryl, heteroaryl, aryl(C,-C 4 )alkyl, aryl(C,-C 4 )heteroalkyl, heteroaryl(C r C 4 )alkyl and heteroaryl(C , -C 4 )heteroalkyl ; and Ar is a substituted aryl group selected from the group consisting of: wherein X' and X 2 are each independently selected from the group consisting of F, Cl and Br. 2. A compound of claim 1, wherein Ar is selected from the group consisting of 3. A compound of claim 1. wherein Ar is pentafluorophenyl. 4. A compound of claim 1, wherein Ar is 2,3,4,5-tetrafluorophenyl. 5. A compound of claim 1, wherein Ar is 3,4,5-tπmethoxyphenyl. 6. A compound of claim 1, wherein Ar is 3-methoxy-4,5-methylenedιoxyphenyl 7. A compound of claim 1, wherein R 1 is hydrogen. 8. A compound of claim 1, wherein R 2 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C r C 3 )alkoxy 9. A compound of claim 1, wherein R 3 is selected from the group consisting of hydrogen, (C r C 3 )alkyl, -OR" and -NR n R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C r C 3 )heteroalkyl 10. A compound of claim 1, having the formula: 11. A compound of claim 10, wherein R' is hydrogen. 12. A compound of claim 10, wherein R 2 is selected from the group consisting of hydrogen, fluonne, (C r C 3 )alkyl and (C,-C 3 )alkoxy 13. A compound of claim 10, wherein R 3 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C,-C 3 )heteroalkyl 14. A compound of claim 1, having the formula: 15. A compound of claim 14, wherein R' is hydrogen. 16. A compound of claim 14, wherein R 2 is selected from the group consisting of hydrogen, (C 1 -C 3 )alkyl and (C r C 3 )alkoxy. 17. A compound of claim 14, wherein R 3 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R' 2 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C r C 3 )heteroalkyl. 18. A compound of claim 10, wherein R' is hydrogen, R 2 is hydrogen and R 3 is selected from the group consisting of methoxy, ethoxy, methyl, dimethylamino and hydroxy. 19. A compound of claim 1, having the formula: 20. A compound of claim 19, wherein R 1 is hydrogen. 21. A compound of claim 19, wherein R 2 is selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C r C 3 )alkoxy. 22. A compound of claim 19, wherein R 3 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C,-C 3 )heteroalkyl. 23. A compound of claim 1, having the formula: 24. A compound of claim 23, wherein R' is hydrogen. 25. A compound of claim 23, wherein R 2 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C r C 3 )alkoxy. 26. A compound of claim 23, wherein R 3 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl, -OR" and -NR"R 12 , wherein R 11 and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C,-C 3 )heteroalkyl. 27. A compound of claim 23, wherein R 1 is hydrogen, R 2 is hydrogen and R 3 is selected from the group consisting of methoxy, ethoxy, methyl, dimethylamino and hydroxy. 28. A compound of claim 1, having the formula: 29. A compound of claim 1, having the formula: 30. A compound of claim 1, having the formula: 31. A compound of claim 1, having the formula: 32. A compound of claim 1, having the formula: 33. A compound of claim 1, having the formula: 34. A compound of claim 1, having the formula: 35. A compound of claim 1, having the formula: 36. A compound of claim 1, having the formula: 37. A method of treating or preventing a disease state charactenzed by abnormally high levels of low density lipoprotein particles or cholesterol in the blood, or by an abnormally high level of cell proliferation, which method compπses adrmnisteπng to a mammalian subject in need thereof a therapeutically effective amount of a composition compπsmg a compound of formula: or a pharmaceutically acceptable salt thereof, wherein R' IS a member selected from the group consisting of hydrogen, (C,-C 6 )alkyl and (C r C 6 )heteroalkyl; R 2 and R 3 are each independently selected from the group consisting of hydrogen, halogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 8 )alkyl and (C ; - C 8 )heteroalkyl; or R 2 and R 3 , when attached to adjacent carbon atoms, can be linked together to form a fused 5-, 6- or 7-membered nng; R 4 and R 5 are each independently selected from the group consisting of hydrogen, (C,-C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, heteroaryl, aryl(C,-C 4 )alkyl, aryl(C,- C 4 )heteroalkyl, heteroaryl(C,-C 4 )alkyl and heteroaryl(C,-C 4 )heteroalkyl, and are optionally linked together to form a 5-, 6- or 7-membered nng; or R 4 represents a single bond to the phenyl πng beaπng the phosphoryl group and R 5 is selected from the group consisting of hydrogen, (C,-C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, heteroaryl, aryl(C,-C 4 )alkyl, aryl(C,-C 4 )heteroalkyl, heteroaryl(C,-C 4 )alkyl and heteroaryl(C,-C 4 )heteroalkyl; and Ar is a substituted aryl group selected from the group consisting of. wherein X 1 and X 2 are each independently selected from the group consisting of F, Cl and Br. 38. A method in accordance with claim 37, wherein Ar is selected from the group consisting of 39. A method in accordance with claim 37, wherein Ar is pentafluorophenyl 40. A method in accordance with claim 37, wherein Ar is 2,3,4,5-tetrafluorophenyl. 41. A method in accordance with claim 37, wherein Ar is 3,4,5-tπmethoxylphenyl 42. A method in accordance with claim 37, wherein Ar is 3-methoxy-4,5- methylenedioxyphenyl . 43. A method in accordance with claim 37, wherein R 1 is hydrogen. 44. A method in accordance with claim 37, wherein R 2 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C r C 3 )alkoxy. 45. A method in accordance with claim 37, wherein R 3 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C,- C 3 )heteroalkyl 46. A method in accordance with claim 37, wherein the disease state is cancer or a cancerous condition. 47. A method in accordance with claim 37. wherein the prohferative disease state is infection by a microorganism 48. A method in accordance with claim 37, wherein the prohferative disease state is psonasis 49. A method in accordance with claim 37, wherein the prohferative disease state is vascular restenosis 50. A method in accordance with claim 37, wherein the disease state is hypercholesterolemia or another disease state associated with abnormally high levels of cholesterol or lipoproteins. 51. A method in accordance with claim 37, wherein the compound is administered orally. 52. A method in accordance with claim 37, wherein the compound is administered intravenously or intramuscularly. 53. A pharmaceutical composition compπsmg a pharmaceutically acceptable excipient and a compound having the formula: or a pharmaceutically acceptable salt thereof, wherein R' is a member selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl and (C,-C 6 )heteroalkyl, R 2 and R 3 are each independently selected from the group consisting of hydrogen, halogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, -OR" and -NR"R 12 , w herein R" and R' 2 are each independently selected from the group consisting of hydrogen, (C,-C 8 )alkyl and (C,-C 8 )heteroalkyl; or R 2 and R 3 , when attached to adjacent carbon atoms, can be linked together to form a fused 5-, 6- or 7-membered nng, R 4 and R 5 are each independently selected from the group consisting of hydrogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, aryl, heteroaryl, aryl(C r C 4 )alkyl. aryl(C,- C 4 )heteroalkyl, heteroaryl(C,-C )alkyl and heteroaryl(C r C 4 )heteroalkyl, and are optionally linked together to form a 5-, 6- or 7-membered nng; or R 4 represents a single bond to the phenyl nng beaπng the phosphoryl group and R 5 is selected from the group consisting of hydrogen, (C,-C 8 )alkyl, (C,-C 8 )heteroalkyl, aryl, heteroaryl, aryl(C r C )alkyl, aryl(C,-C 4 )heteroalkyl, heteroary C j -CJalkyl and heteroaryl(C,-C 4 )heteroalkyl; and Ar is a substituted aryl group selected from the group consisting of: wherein X' and X 2 are each independently selected from the group consisting of F, Cl and Br. 54. A composition of claim 53. wherein Ar is selected from the group consisting of 55. A composition of claim 53, wherein Ar is pentafluorophenyl. 56. A composition of claim 53, wherein Ar is 2,3,4,5-tetrafluorophenyl. 57. A composition of claim 53. wherein Ar is 3,4,5-tπmethoxylphenyl. 58. A composition of claim 53. wherein Ar is 3-methoxy-4,5-methylenedιoxyphenyl 59. A composition of claim 53, wherein R 1 is hydrogen. 60. A composition of claim 53, wherein R 2 is selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C r C 3 )alkoxy. 61. A composition of claim 53, wherein R 3 is selected from the group consisting of hydrogen, (C,-C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C,-C 3 )heteroalkyl. 62. A composition of claim 53, having the formula: 63. A composition of claim 62, wherein R 1 is hydrogen. 64. A composition of claim 62, wherein R 2 is selected from the group consisting of hydrogen, fluonne, (C,-C 3 )alkyl and (C r C 3 )alkoxy. 65. A composition of claim 62, wherein R 3 is selected from the group consisting of hydrogen, (C r C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C j -C^heteroalkyl 66. A composition of claim 53, having the formula. 67. A composition of claim 66, wherein R' is hydrogen. 68. A composition of claim 66, wherein R 2 is selected from the group consisting of hydrogen, fluonne, (C r C 3 )alkyl and (C r C 3 )alkoxy 69. A composition of claim 66, wherein R is selected from the group consisting ot hydrogen, (C,-C,)alkyl, -OR" and -NR"R 12 , wherein R" and R' 2 are each independently selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C,-C 3 )heteroalkyl 70. A composition of claim 66, wherein R 1 is hydrogen, R 2 is hydrogen and R 3 is selected from the group consisting of methoxy, ethoxy, methyl, dimethylamino and hydroxy 71. A composition of claim 53, having the formula: 72. A composition of claim 71, wherein R' is hydrogen. 73. A composition of claim 71, wherein R 2 is selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C r C 3 )alkoxy. 74. A composition of claim 71, wherein R 3 is selected from the group consisting of hydrogen, (C r C 3 )alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C r C 3 )alkyl and (C,-C 3 )heteroalkyl. 75. A composition of claim 53, having the formula: 76. A composition of claim 75, wherein R' is hydrogen. 77. A composition of claim 75, wherein R 2 is selected from the group consisting of hydrogen, (C,-C )alkyl and (C,-C 3 )alkoxy. 78. A composition of claim 75, wherein R 3 is selected from the group consisting of hydrogen, (C,-C,)alkyl, -OR" and -NR"R 12 , wherein R" and R 12 are each independently selected from the group consisting of hydrogen, (C,-C 3 )alkyl and (C,-C 3 )heteroalkyl. 79. A composition of claim 75, wherein R 1 is hydrogen, R 2 is hydrogen and R 3 is selected from the group consisting of methoxy, ethoxy, methyl, dimethylamino and hydroxy.

Inventors: HOUZE JONATHAN B, HOUZE, JONATHAN, B.
Applicants: TULARIK INC, TULARIK INC.
Application year: 1999
Main classification: C07F9
IPC codes: A61K31, A61P3, A61P9, A61P17, A61P31, A61P35, C07F9